We are live on ! Find out more
SLNOW

Soleno Therapeutics, Inc. Series A Warrant
SLNOW

Delisted

SLNOW was delisted on the 8th of November, 2019.

Back to rankings

2 hedge funds and large institutions have $82K invested in Soleno Therapeutics, Inc. Series A Warrant in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less funds holding

Funds holding: 3 → 2 (-1)

72% less capital invested

Capital invested by funds: $297K → $82K (-$215K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$273K
2
UBS Group
UBS Group
Switzerland
-$32
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$79K – – –
UBS Group
2
UBS Group
Switzerland
$3K -$32 -100 -1%
6CM
3
683 Capital Management
New York
– -$273K -602,443 Closed

SLNOW Hedge Fund Activity: Q2 2018 in Review

2 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics, Inc. Series A Warrant (SLNOW) for Q2 2018, worth a combined $82K — down 72% from $297K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of SLNOW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest seller was 683 Capital Management, exiting entirely with an estimated $273K sold.

  • 2 institutional investors held Soleno Therapeutics, Inc. Series A Warrant (SLNOW) as of Q2 2018, down from 3 in Q1 2018.
  • Funds reported $82K of Soleno Therapeutics, Inc. Series A Warrant stock for Q2 2018, down 72% quarter-over-quarter.
  • 0 funds opened new Soleno Therapeutics, Inc. Series A Warrant positions in Q2 2018 and 1 closed out, a net change of -1 holder.
  • The largest Soleno Therapeutics, Inc. Series A Warrant seller in Q2 2018 was 683 Capital Management, an estimated $273K sold.

Based on aggregated 13F filings for Q2 2018.